You need the Flash Player version 8.0.0.0 or higher and a JavaScript enabled browser to view this content

Proactive investorsLogo Proactive Investors UK Website

Search field
Get Adobe Flash Player Download
Flash
Player ►

And
Enable
Javascript

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Additional information
Additional Information
Market: ASX
Sector: Pharma & Biotech
Epic: BNO
News: Latest news
Web Site: Bionomics Limited
Other Articles: 28-06-201021-06-201007-06-2010

RSS - Subscribe to the News Today on Proactive UK ▼

Saturday September 04, 06:00Serving up support at Babcock

Support services have been among the worst performing sectors over the past month as revenue fears from the government’s austerity measures weigh heavily on the sector.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive NA ▼

Friday September 03, 11:40 Goldcorp snatches Andean Resources in $3.6bn deal, trumping Eldorado`s earlier bid

Both companies are vying for Andean`s Cerro Negro gold project, which is an advanced-stage, high-grade vein system, comprising 215 square kilometers. It currently has indicated resources of 2.54 million ounces of gold and 23.56 million ounces of silver, while inferred resources total 523,000 ounces of gold and 3.12 million ounces of silver.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Wednesday September 01, 10:25Green Dragon Gas reports significant growth as China’s thirst for energy continues

China's thirst for energy resources has continued with an increased focus on domestic supplies of gas, Green Dragon Gas chairman Randeep Grewal said today. In the company's interim results, [...]

FULL ARTICLE ►
Bionomics Limited

Bionomics Limited

Bionomics (ASX: BNO) is a productive drug discovery and development engine room focused on new treatments for cancer and serious disorders of the central nervous system (CNS). Through application of its proprietary technology platforms, MultiCore®, Angene® and ionX®.

The company has generated multiple drug candidates and targets in the therapeutic areas of Cancer, Anxiety, Multiple Sclerosis and Epilepsy. The company has a strong out-license record in conjunction with its in-house development program which has seen two highly promising drugs enter clinical trials in the past two years.

CLICK HERE FOR FULL ANALYSIS OF BIONOMICS LIMITED
Monday, June 21, 2010

Bionomics' anti anxiety compound BNC210 Phase 1 trial is successful

company news image

Drug discovery and development company Bionomics (ASX: BNO) has continued the spate of good news with its anti-anxiety drug compound BNC210 and second Phase 1 clinical trial results, that have successfully established a four-fold increase in blood drug levels following food intake.

The objective was to determine whether administration of BNC210 with food alters blood levels of the drug. The results expand the dosing range to be used in treatment of of anxiety and depression, establishing a safety profile for the compound, with no significant side effects from useage.

Dr Deborah Rathjen Bionomics’ CEO & managing director explained that “many common drugs are taken either with food or following a meal. The increased exposure seen when BNC210 is given with food expands the potential dosing range to be used in its continued development for the treatment of anxiety and depression".

Rathjen said "it has allowed us to identify the doses to be used in the planned Phase Ib studies of BNC210. The data also suggests that lower doses of BNC210 may be effective when the drug is given with food”.

“This latest data also confirms the results of the initial Phase I clinical trial of BNC210 which indicated that BNC210 was well tolerated at high doses and free of significant side-effects”, she added.

The placebo controlled and blinded trial was conducted in healthy male volunteers at the Pain and Anaesthesia Research Clinic (PARC) within the Royal Adelaide Hospital and Professor Paul Rolan was the Principal Investigator.

Among the secondary objectives of this trial is the evaluation of potential biomarkers showing BNC210 effects. These include the determination of stress hormone levels.

These tests are currently in progress with data anticipated to be available next quarter.

Two Phase Ib clinical trials of BNC210 are anticipated to commence next quarter. The first of the new trials will evaluate BNC210 effects when anxiety is induced in healthy subjects whilst the second trial will evaluate BNC210 effects on the brain using electroencephalograph (EEG) measurements. The trials will continue to look at whether side effects such as sedation or memory impairment, are associated with the administration of BNC210.

AddThis Feed Button
Register here to be notified of Proactiveinvestors One2One Forums.

Other Bionomics Limited articles


Other Bionomics Limited news

More news ►

Investors interested in Bionomics Limited recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.